Beneficient Group L.P. (BENF)

Overview

Imugene Limited is a pioneering clinical stage immuno-oncology company based in Sydney, Australia, established in 1986. The company focuses on developing a diverse array of immunotherapies designed to activate the immune system of cancer patients for the eradication of tumors. Imugene's commitment to innovation in cancer treatment is demonstrated through its collaboration with Arovella Therapeutics Ltd and a research partnership with RenovoRx, Inc. These collaborations aim to enhance the efficacy of treating and accessing difficult-to-treat tumors through advanced oncolytic virus therapy and integrated cell therapy platforms.

Products and Services

• HER-Vaxx:

  A leading product of Imugene, HER-Vaxx, targets HER2-positive cancers, including gastric and breast cancers, by stimulating a polyclonal antibody response against HER2/neu receptors. Currently undergoing a phase 2 study for gastric cancer, HER-Vaxx represents a significant advancement in targeted cancer immunotherapy, offering hope for patients with these aggressive forms of cancer.

• PD1-Vaxx:

  Another innovative product in Imugene's portfolio, the PD1-Vaxx vaccine, is designed to block PD-1 signalling, thereby inducing the body to produce polyclonal antibodies. This mechanism is crucial for enhancing the immune system's capability to fight cancer. PD1-Vaxx is currently in a phase I trial, showcasing Imugene's dedication to expanding its range of cancer immunotherapies.

• CF33:

  Imugene is also developing CF33, a multifaceted oncolytic virus derived from various genomic sequences of vaccinia virus strains. This approach aims to generate a potent virus capable of effectively targeting and eliminating cancer cells. The innovative nature of CF33 highlights Imugene's commitment to exploring diverse therapeutic strategies to combat cancer.